BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

DxNA and PathoGene LLC Announce Completion of Staphylococcus Assay License Agreement and Letter of Intent for DxNA to Acquire PathoGene


7/17/2013 8:29:14 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

St George, Utah, July 15, 2013 DxNA LLC and PathoGene LLC announced today they have signed a definitive License Agreement under which DxNA will acquire exclusive rights for Unit Dose Platform Applications of PathoGene’s “Next Generation” multiplexed Staphylococcus MRSA+ assay on DxNA’s Real Time PCR GeneSTAT platform. Terms of the agreement include upfront and milestone payments as well as ongoing royalties. In addition to the License Agreement, the two companies have agreed to a Letter of Intent under which DxNA would acquire PathoGene. This transaction is expected to occur in the next 6 months contingent on satisfactory completion of due diligence and other contingencies. Financial terms contained in the LOI were not disclosed.

Pathogene’s next generation Staphylococcus assay is clearly differentiated from current commercially available MRSA assays in that it provides rapid identification and drug resistance information for Staphylococcus infections, one of the most common hospital acquired infections. In combination with the GeneSTAT platform, this capability can be delivered to almost any healthcare setting due to its portability and “point of care” design. “In addition to testing for MRSA, Pathogene’s assay also detects multi-drug resistant Coagulase Negative Staphylococcus strains, which are actually much more common infections than MRSA. This is a significant step forward compared to current diagnostic methods and allows the assay to rapidly identify and differentiate three of the most common pathogens of hospital acquired infections - surgical site infections, medical device infections and skin and soft tissue infections - in a single multiplexed assay. This provides information to physicians in about an hour that is critical to treatment decisions that save lives, improve patient outcomes and reduce treatment costs.” said Todd Snowden, PathoGene President and CEO

”Pathogene’s novel approach with this Staph assay provides rapid clinical answers that impact patient care, costs and outcomes making the assay an ideal complement to our GeneSTAT platform. The use of the assay for diagnostics represents a combined $650M market opportunity in the US and the EU”, said David Taus, DxNA President and CEO. DxNA’s Real Time PCR GeneSTAT platform for molecular diagnostic infectious disease testing is uniquely postioned to meet the on-site Staph diagnostic testing needs of Hospitals, Point of Care, Long Term Care and Urgent Care Centers. The GeneSTAT analyzer with the Staph multiplexed test cartridge provides the performance, ease of use, speed, portability and economics required for Staph diagnostic testing to be broadly adopted in these clinical settings.

About DxNA LLC

DxNA LLC is a privately owned Limited Liability Company located in St. George, Utah. DxNA develops and commercially manufactures molecular-based diagnostic assays formatted in a unique and proprietary test cartridge designed for analysis by its proprietary GeneSTAT® analyzer. The test cartridges, together with the GeneSTAT analyzer make up DxNA’s proprietary GeneSTAT® Platform. The current assays are both DNA- and/or RNA-based “multiplexed” tests for “real time” detection of infectious disease agents in humans, and animals or of biological contaminants in the environment. DxNA combines proprietary intellectual property with industry proven technology into the GeneSTAT Platform that the Company believes to be unique in the industry. The GeneSTAT offers unmatched simplicity and control in the processing of specimens. The Platform is comprised of an analyzer and a single-use test cartridge, and can be run with minimal training in either laboratory or field settings accepting a number of specimen types.

PathoGene is a privately held Limited Liability Company located in Flagstaff, Arizona. PathoGene improves patient outcomes and healthcare quality while lowering healthcare costs through the development and worldwide commercialization of novel, patented, molecular diagnostic tests for infectious diseases, particularly those that are: highly resistant to antibiotics, associated with hospital acquired infections (HAI), or where effective diagnostics do not exist. For more information about PathoGene please visit their website at www.pathogene.com.

CONTACTS

DxNA

For Inquiries

Jim Maples

DxNA LLC

p. 435.628.0324

www.dxna.com

PathoGene

For Inquiries

Todd Snowden

PathoGene

P 928.863.3248

www.pathogene.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

DxNA
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES